kras g12c

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

BI-2865 is a non-covalent pan-KRAS inhibitor.BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively.BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants[1] . BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants, with an average IC50 value of approximately 140 nM.[1]

Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors.

Divarasib (GDC-6036) (GDC-6036) is an investigational, oral, high-potency and selective KRAS G12C inhibitor with an IC50 of < 0.01 μM. Divarasib irreversibly locks KRAS G12C oncoprotein in an inactive state and inhibits tumor cell growth. It is being investigated for use in solid tumors, including non-small cell lung and colorectal cancers and other types of cancer.

Adagrasib (MRTX849) is an orally active and selective covalent inhibitor of KRAS G12C. Adagrasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Adagrasib exhibits inhibitory activity against KRAS G12C mutant tumors.

(S)-AMG-510 is the S-type compound of AMG-510 (Sotorasib), which effectively and selectively inhibits KRASG12C through covalent interaction with mutant cysteine, thereby promoting clinical efficacy in KRASG12C tumors.

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

PROTAC KRAS G12C degrader-2 (compound 432) acts as a bifunctional modulator, enhancing the hydrolysis of K-Ras protein. One end of this compound features a cereblon inhibitor of apoptosis proteins (IAP), while the other end contains a moiety that binds to KRAS [1].

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 22 is a specific inhibitor of the KRAS G12C mutation.

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12C inhibitor 20 is an inhibitor specifically targeting the KRAS G12C mutation.

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

BI-0474 is a potent KRASG12C inhibitor that inhibits GDP-KRAS::SOS1 protein-protein interactions with an IC50 value of 7.0 nM.BI-0474 exhibits significant antiproliferative activity against NCI-H358 cells harboring the G12C mutation, and shows significant anti-tumor activity in a non-small cell lung cancer xenograft model. activity.BI-0474 can be used for cancer research.

PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cells [1].

KRAS G12C inhibitor 21 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12C Inhibitor 41 is a potent agent targeting the KRAS G12C mutation within the Ras family of proteins, which are crucial for intracellular signaling related to growth and development. This compound holds significant potential for advancing research in cancers mediated by KRAS G12C.

KRAS G12C Inhibitor 35 is a potent suppressor of KRAS G12C, targeting a crucial member of the Ras protein family which significantly impacts cellular growth and development. This compound holds promise for investigating cancer driven by KRAS G12C mutations.

KRAS G12C Inhibitor 39, a potent antagonist, specifically targets the KRAS G12C mutation, a prime focus in pharmaceutical cancer research. This compound shows promise for investigating KRAS G12C-mediated cancer.